Wells Fargo’s KalVista Pharmaceuticals KALV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$286K Buy
25,324
+2,462
+11% +$27.8K ﹤0.01% 4159
2025
Q1
$264K Buy
22,862
+2,697
+13% +$31.1K ﹤0.01% 4072
2024
Q4
$171K Buy
20,165
+4,543
+29% +$38.5K ﹤0.01% 4400
2024
Q3
$181K Sell
15,622
-310
-2% -$3.59K ﹤0.01% 4264
2024
Q2
$188K Buy
15,932
+1,373
+9% +$16.2K ﹤0.01% 4199
2024
Q1
$173K Buy
14,559
+3,728
+34% +$44.2K ﹤0.01% 4198
2023
Q4
$133K Buy
10,831
+3,400
+46% +$41.7K ﹤0.01% 4333
2023
Q3
$71.6K Sell
7,431
-3,153
-30% -$30.4K ﹤0.01% 4636
2023
Q2
$95.3K Buy
10,584
+5,027
+90% +$45.2K ﹤0.01% 4804
2023
Q1
$43.7K Buy
5,557
+4,317
+348% +$33.9K ﹤0.01% 4938
2022
Q4
$8.38K Sell
1,240
-8,021
-87% -$54.2K ﹤0.01% 5295
2022
Q3
$134K Sell
9,261
-267
-3% -$3.86K ﹤0.01% 4168
2022
Q2
$94K Sell
9,528
-4,238
-31% -$41.8K ﹤0.01% 4417
2022
Q1
$203K Sell
13,766
-7,743
-36% -$114K ﹤0.01% 4669
2021
Q4
$284K Sell
21,509
-58,687
-73% -$775K ﹤0.01% 4718
2021
Q3
$1.4M Sell
80,196
-6,111
-7% -$107K ﹤0.01% 3754
2021
Q2
$2.07M Buy
86,307
+55,998
+185% +$1.34M ﹤0.01% 3486
2021
Q1
$779K Sell
30,309
-7,868
-21% -$202K ﹤0.01% 4141
2020
Q4
$726K Sell
38,177
-11,604
-23% -$221K ﹤0.01% 4186
2020
Q3
$627K Buy
49,781
+2,076
+4% +$26.1K ﹤0.01% 4086
2020
Q2
$578K Buy
47,705
+9,707
+26% +$118K ﹤0.01% 4109
2020
Q1
$292K Sell
37,998
-5,353
-12% -$41.1K ﹤0.01% 4287
2019
Q4
$773K Sell
43,351
-934
-2% -$16.7K ﹤0.01% 3964
2019
Q3
$513K Buy
44,285
+8,575
+24% +$99.3K ﹤0.01% 4249
2019
Q2
$791K Buy
35,710
+1,103
+3% +$24.4K ﹤0.01% 3980
2019
Q1
$990K Buy
34,607
+88
+0.3% +$2.52K ﹤0.01% 3847
2018
Q4
$682K Buy
34,519
+7,451
+28% +$147K ﹤0.01% 4023
2018
Q3
$598K Buy
+27,068
New +$598K ﹤0.01% 4226
2016
Q2
Sell
-165
Closed -$1K 5853
2016
Q1
$1K Buy
165
+160
+3,200% +$970 ﹤0.01% 5817
2015
Q4
$0 Hold
5
﹤0.01% 5975
2015
Q3
$0 Sell
5
-39
-89% ﹤0.01% 5977
2015
Q2
$4K Buy
+44
New +$4K ﹤0.01% 5778